Genetic modifiers of respiratory function in Duchenne muscular dystrophy

Respiratory insufficiency is a major complication of Duchenne muscular dystrophy (DMD). Its progression shows considerable interindividual variability, which has been less thoroughly characterized and understood than in skeletal muscle. We collected pulmonary function testing (PFT) data from a large retrospective cohort followed at Centers collaborating in the Italian DMD Network. Furthermore, we analyzed PFT associations with different DMD mutation types, and with genetic variants in SPP1, LTBP4, CD40, and ACTN3, known to modify skeletal muscle weakness in DMD. Genetic association findings were independently validated in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study (CINRG‐DNHS).

[1]  V. Ricotti,et al.  Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study , 2019, Neuromuscular Disorders.

[2]  J. Mendell,et al.  Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy , 2019, Journal of neuromuscular diseases.

[3]  V. Vieland,et al.  Long‐range genomic regulators of THBS1 and LTBP4 modify disease severity in duchenne muscular dystrophy , 2018, Annals of neurology.

[4]  S. Nelson,et al.  DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype , 2018, Human mutation.

[5]  Carla M Bann,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management , 2018, The Lancet Neurology.

[6]  S. Pandya,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management , 2018, The Lancet Neurology.

[7]  A. Aliverti,et al.  Evolution of respiratory function in Duchenne muscular dystrophy from childhood to adulthood , 2018, European Respiratory Journal.

[8]  E. Hoffman,et al.  Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study , 2017, The Lancet.

[9]  M. Reinders,et al.  Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy , 2017, Scientific Reports.

[10]  Cinrg investigators for PubMed.  Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids. , 2017 .

[11]  Luca Bello,et al.  SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells , 2017, Human molecular genetics.

[12]  E. McNally,et al.  Outside in: The matrix as a modifier of muscular dystrophy. , 2017, Biochimica et biophysica acta. Molecular cell research.

[13]  A. Krieg,et al.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga , 2017, Nucleic acid therapeutics.

[14]  E. Hoffman,et al.  Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy , 2017, Nature Communications.

[15]  E. Pegoraro,et al.  Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy , 2016, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[16]  E. Hoffman,et al.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy. , 2016, American journal of human genetics.

[17]  E. Hoffman,et al.  P.103 DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study , 2016, Neuromuscular Disorders.

[18]  H. Topaloglu,et al.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy , 2016, Neurology.

[19]  A. Manzur,et al.  Corticosteroids for the treatment of Duchenne muscular dystrophy. , 2016, The Cochrane database of systematic reviews.

[20]  R. Moxley,et al.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy , 2016, Neurology.

[21]  E. Hoffman,et al.  Immune-mediated pathology in Duchenne muscular dystrophy , 2015, Science Translational Medicine.

[22]  E. Hoffman,et al.  Genetic modifiers of ambulation in the cooperative international Neuromuscular research group Duchenne natural history study , 2015, Annals of neurology.

[23]  M. Benton,et al.  Characterization of pulmonary function in Duchenne Muscular Dystrophy , 2015, Pediatric pulmonology.

[24]  Francesco Muntoni,et al.  Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[25]  Y. Takeshima,et al.  A novel splicing silencer generated by DMD exon 45 deletion junction could explain upstream exon 44 skipping that modifies dystrophinopathy , 2014, Journal of Human Genetics.

[26]  G. Comi,et al.  6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes , 2014, PloS one.

[27]  Annemieke Aartsma-Rus,et al.  Prolonged Ambulation in Duchenne Patients with a Mutation Amenable to Exon 44 Skipping. , 2014, Journal of neuromuscular diseases.

[28]  C. Pagel,et al.  Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle , 2013, Journal of Cell Communication and Signaling.

[29]  Jay J. Han,et al.  The cooperative international neuromuscular research group duchenne natural history study—a longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used , 2013, Muscle & nerve.

[30]  Craig McDonald,et al.  LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy , 2013, Annals of neurology.

[31]  C. Angelini.  Muscular dystrophy: Causes and management , 2013 .

[32]  G. Comi,et al.  Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy , 2012, Neurology.

[33]  J. Pépin,et al.  Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[34]  Anna Carla Turconi,et al.  Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up , 2011, Journal of Neurology.

[35]  G. Lanfranchi,et al.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy , 2010, Neurology.

[36]  S. Nelson,et al.  Predicting the severity of Duchenne muscular dystrophy , 2010, Neurology.

[37]  Y. W. Chen,et al.  Early onset of inflammation and later involvement of TGFβ in Duchenne muscular dystrophy , 2005, Neurology.

[38]  M. Le Cunff,et al.  Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. , 2002, American journal of physiology. Cell physiology.

[39]  N. Bresolin,et al.  Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy , 2000, Neurology.

[40]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[41]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[42]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[43]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[44]  J. Hodgkin.  Ventilatory assistance. , 1979, American journal of surgery.